Optimizing Patient Outcomes in Diabetic Retinopathy

Released On
January 21, 2020

Expires On
January 21, 2021

Media Type

Completion Time
60 minutes


Scroll to the Bottom of this Information to Begin this Course

This activity is provided by MedicusCME.


This activity is supported by an educational grant from Regeneron Pharmaceuticals.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

Content and educational strategies have been designed to facilitate behavior change in ophthalmologists, primary care physicians, residents and fellows, physician assistants, nurse practitioners, optomistrists, and all health care providers (HCPs) who care for patients at risk for diabetes and associated retinal disease.

Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Identify and compare current treatment pathways for diabetic retinopathy patients and diabetic macular edema and their impact on patient outcomes.
  2. Develop consensus on factors responsible for differences in referral pathways for diabetic retinopathy patients and conceptualize patient referral guidelines.
  3. Synthesize key outstanding questions regarding timing of patient referral from optometrist to ophthalmologist in diabetic retinopathy.
  4. Present recommendations for actions to improve diabetic retinopathy patient referrals to achieve optimal patient outcomes.


Charles C Wykoff, MD, PhD

Director of Research, Retina Consultants of Houston
Deputy Chair for Ophthalmology, Blanton Eye Institute
Associate Clinical Professor of Ophthalmology, Weill Cornell Medical College
Houston Methodist Hospital
Houston Texas

Eric W Schneider, MD

Tennessee Retina, Partner and Vitreoretinal Surgeon
Nashville Tennessee

William W Li, MD

President and Chief Executive Officer, The Angiogenesis Foundation
Nashville Tennessee

Brad H. Feldman, MD

Ophthalmologist and Surgeon, Wills Eye Hospital
Clinical Instructor in Ophthalmology, Sidney Kimmel Medical College at Thomas Jefferson University
Philadelphia, Pennsylvania

Steven Haimowitz, MD

President, RealCME

Carol Pashman, MS, RN

President, MedicusCME

Jeff McRae, MS

Grants Administrator, The Angiogenesis Foundation

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of MedicusCME and the Angiogenesis Foundation. MedicusCME is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

MedicusCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MedicusCME’s Policy on Conflict of Interest

It is the policy of MedicusCME to identify and resolve any potential conflicts of interest of anyyone who may be in a position to influence or control the content of an education activity, to assure balance, independence, objectivity and scientific rigor in all of its accredited activities. All faculty and planners are expected to disclose all financial relationships with a commercial interest within the past twelve months.

Disclosures of Conflicts of Interest

Dr. Wykoff acknowledges receipt of consulting fees from Acuela, Alimera Sciences, Allegro, Bayer, DORC, EyePoint, Fosun, ONL Therapeutics, Opthea, Optos, Outlook Therapeutics, Oxurion and PolyPhotonix Takeda for his participation on their respective scientific advisory boards. He acknowledges receipt of research support from Aerie Pharmaceuticals, Aldeyra Therapeutics, Gemini Therapeutics, Graybug Vision, IONIS Pharmaceuticals, Neurotech, Opthea, Outlook Therapeutics, Samsung, Senju Pharmaceuticals and Xbrane Biopharma; and of both consulting fees and research support from Adverum, Aerpio, Allergan, Apellis, Chengdu Kanghong, Clearside Biomedical, Genentech/Roche, Iveric Bio (formerly Ophthotech), Kodiak, Novartis, Optos, Recens Medical, Regenxbio, Regeneron and Santen. Additionally, he owns stock in Regeneron.

All other planners, faculty, authors and presenters of this accredited activity deny any personal or financial relationships with ACCME-defined commercial entities that may constitute any real or perceived conflict of interest.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

By participating in all course content and learning strategies, and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 credits™.

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive CME credit.
  • You must score with an 75% or higher on the post-test to receive credit for this activity.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.


The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.